Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 392, Issue 10152, 2018, Pages 1036-1046

  Gaziano, J Michael ^e,f,g   Brotons, Carlos ^a   Coppolecchia, Rosa ^b   Cricelli, Claudio ^c   Darius, Harald ^d   Gorelick, Philip B ^h,i   Howard, George ^j   Pearson, Thomas A ^k   Rothwell, Peter M ^l   Ruilope, Luis Miguel ^m   Tendera, Michal ⁿ   Tognoni, Gianni ^o  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b BAYER CORPORATION   (United States)

^c Società Italiana di Medicina Generale   (Italy)

^d Department of Cardiology   (Germany)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g VA BOSTON HEALTHCARE SYSTEM   (United States)

^h MICHIGAN STATE UNIVERSITY   (United States)

ⁱ Vascular Neurology Program   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k UNIVERSITY OF FLORIDA HEALTH   (United States)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ MEDICAL UNIVERSITY OF SILESIA   (Poland)

^o MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL HEMORRHAGE; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ASPIRIN; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE;

EID: 85054662254     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31924-X     Document Type: Article

References (22)

1. Guirguis-Blake, JM, Evans, CV, Senger, CA, O'Connor, EA, Whitlock, EP, Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 164 (2016), 804–813.
2. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
3. Smith, SC Jr, Benjamin, EJ, Bonow, RO, et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124 (2011), 2458–2473.
4. Bibbins-Domingo, K, Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 164 (2016), 836–845.
5. Piepoli, MF, Hoes, AW, Agewall, S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
6. Peto, R, Gray, R, Collins, R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296 (1988), 313–316.
7. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 321 (1989), 129–135.
8. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351 (1998), 233–241.
9. Hansson, L, Zanchetti, A, Carruthers, SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998), 1755–1762.
10. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357 (2001), 89–95.
11. Ridker, PM, Cook, NR, Lee, IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005), 1293–1304.
12. Ogawa, H, Nakayama, M, Morimoto, T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008), 2134–2141.
13. Belch, J, MacCuish, A, Campbell, I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840.
14. Fowkes, FG, Price, JF, Stewart, MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303 (2010), 841–848.
15. Ikeda, Y, Shimada, K, Teramoto, T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312 (2014), 2510–2520.
16. US Food and Drug Administration. Citizen Petition Denial Response From FDA to Bayer Healthcare LLC. Docket ID: FDA-1977-N0018. www.regulations.gov/#!documentDetail;D=FDA-1977-N-0018-0101, 2014. (Accessed 3 March 2016)
17. Van't Hof JR, Duval S, Walts A, Kopecky SL, Luepker RV, Hirsch AT. Contemporary primary prevention aspirin use by cardiovascular disease risk: impact of US Preventive Services Task Force recommendations, 2007–2015: a serial, cross-sectional study. J Am Heart Assoc 20173; 6: e006328.
18. International Task Force for Prevention of Coronary Heart Disease. Pocket guide to prevention of coronary heart disease. http://www.sisalombardia.it/pdfs/pocket_guide_engl.pdf, 2003. (Accessed 13 August 2018)
19. National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Executive summary. https://www.nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf, 2001. (Accessed 13 August 2018)
20. European Association of Preventive Cardiology. HeartScore quick calculator. https://heartscore.escardio.org/2012/calc.aspx?model=europelow. (Accessed 13 August 2018)
21. Berkowitz, SD, Granger, CB, Pieper, KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 95 (1997), 2508–2516.
22. Raju, N, Sobieraj-Teague, M, Bosch, J, Eikelboom, JW, Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med 129 (2016), e35–e36.